FIELD: medicine.
SUBSTANCE: invention relates to compounds with the general formula (I), as well as to a method for their production, a pharmaceutical composition based on them, and the use for the treatment of conditions mediated by a sigma receptor.
EFFECT: new compounds are obtained, providing binding to sigma receptors, especially sigma-1, which can be used for the treatment of mediated diseases.
16 cl, 113 ex
Title | Year | Author | Number |
---|---|---|---|
ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIROOUNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY DIRECTED AGAINST PAIN | 2015 |
|
RU2720406C2 |
PIPERAZINE DERIVATIVES, CHARACTERIZED BY MULTIMODAL ACTIVITY ON PAIN | 2014 |
|
RU2709482C1 |
O-SUBSTITUTED DERIVATIVES OF 6-METHYLTRAMADOL, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2286334C2 |
COMBINATION OF SPECIFIC OPIOIDS WITH MUSCARINE ANTAGONISTS FOR INCONTINENCE THERAPY | 2002 |
|
RU2305562C2 |
METHOD FOR PRODUCTION OF HYDROXYLATED CYCLOPENTYL PYRIMIDINE COMPOUNDS | 2013 |
|
RU2643811C2 |
PYRIDAZINE DERIVATIVE INHIBITOR, METHOD OF ITS PREPARATION AND ITS USE | 2020 |
|
RU2807611C2 |
THIAZOLIDINONE COMPOUNDS AND USE THEREOF FOR TREATING MENTAL OR NEUROLOGICAL DISORDERS AND INFLAMMATION, PARTICULARLY NEUROINFLAMMATION | 2015 |
|
RU2734253C2 |
PYRIDINE CARBOXAMIDE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2015 |
|
RU2694899C2 |
LEUKOTRIENE A4-HYDROLASE INHIBITORS | 2014 |
|
RU2690489C2 |
OBESITY TREATMENT | 2019 |
|
RU2822679C2 |
Authors
Dates
2022-09-12—Published
2016-11-15—Filed